MacroGenics
MacroGenics
Explore linked clinical trials.12 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION) | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, cervix disorder, female reproductive system disorder, female reproductive system neoplasm, metastatic malignant neoplasm, neoplasm, uterine disorder | Recruiting | Phase 2 | 2026-09-17 | NCT05475171 | |
| A Study of MGC030 in Participants With Advanced Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Site, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, esophageal cancer, esophageal disorder, gastric neoplasm, gastroesophageal cancer, intestinal disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm, rectal disorder, stomach disorder | Not yet recruiting | Phase 1 | 2026-09-16 | NCT07822399 | |
| Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial] | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 2 | 2026-08-27 | NCT07071961 | |
| Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 2 | 2026-08-21 | NCT02923180 | |
| A Study of MGC026 in Participants With Advanced Solid Tumors | Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Liver Neoplasms, Male Urogenital Diseases, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Prostatic Cancer, Castration-Resistant, Prostatic Neoplasms, Castration-Resistant, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, adenocarcinoma, benign urinary system neoplasm, breast cancer, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, cervix disorder, clear cell renal carcinoma, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, endometrium neoplasm, epithelial neoplasm, esophageal disorder, esophageal squamous cell carcinoma, female reproductive system disorder, female reproductive system neoplasm, gastric cancer, gastric neoplasm, gonadal disorder, head and neck squamous cell carcinoma, hepatocellular carcinoma, intestinal disorder, kidney cancer, kidney disorder, liver disorder, lung disorder, lung neoplasm, male reproductive organ cancer, male reproductive system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, melanocytic neoplasm, melanoma, metastatic malignant neoplasm, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, pancreas disorder, pancreatic neoplasm, primitive neuroectodermal tumor, prostate cancer, prostate disorder, rectal disorder, renal cell carcinoma, respiratory system disorder, respiratory tract neoplasm, sarcoma, skin disorder, skin neoplasm, small cell lung carcinoma, squamous cell carcinoma, squamous cell neoplasm, stomach disorder, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder, uterine disorder | Recruiting | Phase 1 | 2026-08-11 | NCT06242470 | |
| A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies | CD4+/CD56+ hematodermic neoplasm, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Mast Cell Activation Disorders, Mastocytosis, Systemic, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, acute myeloid leukemia, aggressive systemic mastocytosis, bone marrow disorder, classic Hodgkin lymphoma, connective tissue neoplasm, hairy cell leukemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, mastocytosis, myelodysplastic syndrome, myeloid leukemia, neoplasm, skin disorder, skin neoplasm | Active, not recruiting | Phase 1 | 2026-07-28 | NCT05362773 | |
| Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 2 | 2026-07-24 | NCT06014255 | |
| MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Active, not recruiting | Phase 2 | 2026-06-25 | NCT06227546 | |
| A Study of Lorigerlimab in Participants With Advanced Solid Tumors | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, cervical clear cell adenocarcinoma, endometrium neoplasm, fallopian tube clear cell adenocarcinoma, female reproductive system disorder, female reproductive system neoplasm, neoplasm, ovarian clear cell adenocarcinoma, uterine disorder | Recruiting | Phase 2 | 2026-06-02 | NCT06730347 | |
| Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency | pancreatic adenocarcinoma | Not yet recruiting | Phase 2 | 2026-05-04 | NCT07565155 | |
| A Study of MGC028 in Participants With Advanced Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Pancreatic Carcinoma, adenocarcinoma, carcinoma, cholangiocarcinoma, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, intestinal disorder, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm, rectal disorder | Recruiting | Phase 1 | 2026-04-27 | NCT06723236 | |
| MARGetuximab Or Trastuzumab (MARGOT) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2025-11-18 | NCT04425018 |